頁籤選單縮合
| 題 名 | Anthracycline類藥物引起之心毒性=A Review of Anthracycline-Induced Cardiotoxicity |
|---|---|
| 作 者 | 陸昱彬; 陳智芳; 張明志; | 書刊名 | 中華民國癌症醫學會雜誌 |
| 卷 期 | 17:1 2001.03[民90.03] |
| 頁 次 | 頁1-9 |
| 分類號 | 418.31 |
| 關鍵詞 | 心毒性; 抗腫瘤製劑; Anthracycline; Cardiotoxicity; Dexrazoxane; Liposomal doxorubicin; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | Anthracyclines為廣效的抗腫瘤製劑,可治療血液性及實質性腫瘤等惡性病變。但卻因顯著的不良反應-心毒性而使臨床使用受到限制。Anthracyclines引起的心毒性通常為不可逆性且可能進展成鬱血性心衰竭。心毒性的發生率會隨anthracyclines累積劑量之增加而升高。此外,另有許多因素促使anthracyclines引起心肌病變如年齡、心臟病病史、高血壓、先前或同時合併放射性治療...等。 本篇文章回顧了anthracycline類藥品引起心毒性的型式、臨床表徵、危險因子、致病機轉、評估方式及預防方法。使用微脂粒包埋的doxorubicin及具心臟保護作用之dexrazoxane可降低心毒性及改善病患對anthracyclines的耐受性。目前核准用在由cisplatin引起腎毒性的amifostine,其前臨床試驗顯示可預防anthracyclines引起之心毒性。 |
| 英文摘要 | Anthracyclines are potent antineoplastic agents with broad antitumor activity. They are used in the treatment of a variety of malignancies including hemopoietic and solid tumors. However, their use is limited by prominent cardiotoxicity. Anthracycline-induced cardiomyopathy is often irreversible and may lead to congestive heart failure. The incidence of cardiotoxicity increases with higher cumulative anthracycline doses. This is of particular concern when the patient may already be predisposed to cardiomyopathy by other factors such as age, concomitant heart disease, hypertension, prior radiation, etc. We briefly review anthracycline-induced cardiotoxicity, including types of cardiotoxicity, clinical presentation, risk factors, mechanisms, diagnosis and prevention. The technological advance of liposomal encapsulation of doxorubicin with a cardioprotective agent (i.e. dexrazoxane) can reduce cardiotoxicity and improve the tolerance of anthracyclines. Amifostine, which is approved for cisplatininduced nephrotoxicity, has undergone preclinical studies investigating anthracycline-induced cardiotoxicity. |
本系統中英文摘要資訊取自各篇刊載內容。